<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Penicillin G benzathine and penicillin G procaine (mixture of long and intermediate-acting intramuscular): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Penicillin G benzathine and penicillin G procaine (mixture of long and intermediate-acting intramuscular): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Penicillin G benzathine and penicillin G procaine (mixture of long and intermediate-acting intramuscular): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11246" href="/d/html/11246.html" rel="external">see "Penicillin G benzathine and penicillin G procaine (mixture of long and intermediate-acting intramuscular): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="139612" href="/d/html/139612.html" rel="external">see "Penicillin G benzathine and penicillin G procaine (mixture of long and intermediate-acting intramuscular): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709200"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Appropriate administration:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Not for IV use. Do not inject IV or admix with other IV solutions. There have been reports of inadvertent IV administration of penicillin G benzathine, which has been associated with cardiorespiratory arrest and death. Prior to administration of this drug, carefully read the Warnings, Adverse Reactions, and Administration and Dosage sections of the labeling.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F207718"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Bicillin C-R;</li>
<li>Bicillin C-R 900/300</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F207728"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Penicillin</li></ul></div>
<div class="block doa drugH1Div" id="F207721"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Doses are expressed in units of total penicillin. Penicillin G benzathine and penicillin G procaine is available as 2 separate products: Bicillin C-R 900/300 (benzathine and procaine components in a 3:1 ratio and only approved in infants and children) and Bicillin C-R (benzathine and procaine components in a 1:1 ratio); use caution to ensure appropriate product selection as they are not interchangeable. Bicillin C-R 600,000 unit and 2.4 million unit syringes have been discontinued in the United States for &gt;1 year. Bicillin C-R 1.2 million unit syringes are still available.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ab593f35-8b1b-4f56-b574-3c51bed3b1dc">Pneumococcal infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumococcal infections:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Not to be used for treatment of pneumococcal meningitis. For meningitis and other severe pneumococcal infections, use other formulations of penicillin.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 1.2 million units on day 1; may be repeated every 2 or 3 days until afebrile for 48 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3f2098d-7a15-436e-bc6b-422791b57466">
<i>Streptococcus</i>, group A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Streptococcus</i>, group A:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For treatment of group A streptococcal pharyngitis in adults, penicillin G benzathine (Bicillin L-A) is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 2.4 million units as a single dose. Alternative dosing: 1.2 million units on day 1 and 1.2 million units on day 3.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991610"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988838"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F207722"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F207725"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="139612" href="/d/html/139612.html" rel="external">see "Penicillin G benzathine and penicillin G procaine (mixture of long and intermediate-acting intramuscular): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Doses are expressed in units of total penicillin. Penicillin G benzathine and penicillin G procaine is available as 2 separate products: Bicillin C-R 900/300 (benzathine and procaine components in a 3:1 ratio and only approved in infants and children) and Bicillin C-R (benzathine and procaine components in a 1:1 ratio); use caution to ensure appropriate product selection; they are not interchangeable. Bicillin C-R 600,000 unit and 2.4 million unit syringes have been discontinued in the United States for more than 1 year; Bicillin C-R 1.2 million unit syringes are still available, but syringes do not contain graduation marks.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="53296b53-2029-47ae-ba1b-e74970b78226">Otitis media or pneumonia caused by <i>Streptococcus pneumoniae</i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media or pneumonia caused by <i>Streptococcus pneumoniae</i>:</b>
<b>Note: </b>Current guidelines do not include penicillin G benzathine and penicillin G procaine as a therapeutic option (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439909','lexi-content-ref-21880587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439909','lexi-content-ref-21880587'])">Ref</a></span>). For severe cases, use other forms of penicillin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children:</p>
<p style="text-indent:-2em;margin-left:6em;">Bicillin C-R: IM: 600,000 units every 2 to 3 days until afebrile for 48 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Bicillin C-R 900/300: IM: 1.2 million units every 2 or 3 days until afebrile for 48 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4400e32c-593c-400a-95dd-14bf74ee1d54">
<i>Streptococcus</i>, group A; pharyngitis/tonsillitis or skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Streptococcus,</i> group A; pharyngitis/tonsillitis or skin and soft tissue infection (SSTI): Note:</b> Although FDA approved, the combination product with penicillin G benzathine and penicillin G procaine is not included in current SSTI guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Bicillin C-R: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;14 kg: IM: 600,000 units in a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">14 to &lt;27 kg: IM: 900,000 units to 1.2 million units in a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">≥27 kg: IM: 2.4 million units in a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Alternatively, 50% of the total dose can be administered on day 1 and 50% on day 3.</p>
<p style="text-indent:-2em;margin-left:4em;">Bicillin C-R 900/300: Infants and Children: IM: 1.2 million units in a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-765515','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-765515','lexi-content-ref-manu.1'])">Ref</a></span>). <b>Note: </b>Efficacy in heavier pediatric patients (eg, weight &gt;27 kg) is unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19246689','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19246689','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51152720"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51152721"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F207702"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal<i>: Clostridioides-difficile</i> associated diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms</p></div>
<div class="block coi drugH1Div" id="F207714"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to penicillin(s), procaine, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F207699"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity (including cephalosporins) and/or a history of sensitivity to multiple allergens. Serious anaphylactic reactions require immediate treatment with supportive care measures and airway protection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fibrosis and atrophy: Quadriceps femoris fibrosis and atrophy have been reported following repeated IM injections of penicillins into the anterolateral thigh.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: Has been reported with local anesthetics, including procaine; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants &lt;6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).</p>
<p style="text-indent:-2em;margin-left:4em;">• Procaine sensitivity: If there is a history of hypersensitivity to procaine, test with 0.1 mL of procaine 1% or 2% solution. If erythema, wheal, flare, or eruption occurs, patient may be sensitive to procaine; do not use penicillin G procaine in these patients. Treat sensitivity with supportive measures, including antihistamines.</p>
<p style="text-indent:-2em;margin-left:4em;">• Severe cutaneous adverse reactions: Severe cutaneous adverse reactions (SCAR) (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis) have been reported; discontinue immediately if SCAR is suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>Clostridioides</i>
<i>difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate administration: Not for IV use; reports of inadvertent IV administration have been associated with cardiopulmonary arrest and death. Administer by deep IM injection only. Injection into or near an artery or nerve could result in severe neurovascular damage or permanent neurological damage or gangrene possibly requiring amputation, necrosis/sloughing at or surrounding the injection site, or other serious complications.</p>
<p style="text-indent:-2em;margin-left:4em;">• Choice of preparation: Penicillin G benzathine-penicillin G procaine (eg, Bicillin C-R) is not the same preparation as penicillin G procaine. Dispensing errors have occurred (CDC 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">• Prolonged use: Extended duration of therapy or use associated with high serum concentrations (eg, in renal insufficiency) may be associated with an increased risk for some adverse reactions (neutropenia, hemolytic anemia, serum sickness).</p></div>
<div class="block prod-avail drugH1Div" id="F57277578"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Bicillin C-R 600,000 unit and 2.4 million unit syringes have been discontinued in the United States for &gt;1 year. Bicillin C-R 1.2 million unit syringes are still available.</p></div>
<div class="block foc drugH1Div" id="F207710"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, suspension [prefilled syringe]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bicillin C-R: </p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">600,000 units: Penicillin G benzathine 300,000 units and penicillin G procaine 300,000 units per 1 mL (1 mL) [DSC]</p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">1,200,000 units: Penicillin G benzathine 600,000 units and penicillin G procaine 600,000 units per 2 mL (2 mL) </p>
<p style="text-indent:-2em;margin-left:6em;text-align:justify;">2,400,000 units: Penicillin G benzathine 1,200,000 units and penicillin G procaine 1,200,000 units per 4 mL (4 mL) [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bicillin C-R 900/300: 1,200,000 units: Penicillin G benzathine 900,000 units and penicillin G procaine 300,000 units per 2 mL (2 mL)</p></div>
<div class="block geq drugH1Div" id="F207695"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F4380079"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Bicillin C-R 900/300 Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">900000-300000 units/2 mL (per mL): $132.61</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Bicillin C-R Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1200000 units/2 mL (per mL): $132.61</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F207712"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IM: Administer by deep IM injection at a slow, steady rate in the dorsogluteal region (upper outer quadrant of the buttock) or ventrogluteal region (anterolateral thigh). When repeated doses are indicated, vary the injection site. Do not inject near an artery or a nerve; permanent neurological damage or gangrene may result. Do not mix with other IV solutions. <b>Do not administer IV, intravascularly, or intra-arterially. </b></p></div>
<div class="block admp drugH1Div" id="F52613560"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IM: For IM administration only. <b>Do not administer IV, intravascularly, or intra-arterially.</b> Avoid injection near an artery or a nerve; permanent neurological damage or gangrene may result.</p>
<p style="text-indent:-2em;margin-left:2em;">Administer by deep IM injection at a slow, steady rate in the upper outer quadrant of the buttock or anterolateral thigh; in infants and small children, injections in the midlateral aspect of the thigh are preferred. Needle may become blocked if injection is not at a slow, steady rate due to high concentration of suspended material. Dose is usually administered in a single treatment session; multiple IM sites may be required to administer full dose. When repeated doses are indicated, vary the injection site.</p></div>
<div class="block use drugH1Div" id="F207711"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumococcal infections:</b> Treatment of moderately severe pneumonia and otitis media due to susceptible <i>Pneumococcus</i> spp. (eg, <i>Streptococcus pneumoniae</i>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcal infections, group A:</b> Treatment of moderately severe to severe infections, without associated bacteremia, of the upper respiratory tract, scarlet fever, erysipelas, and skin and soft tissue infections due to group A streptococci.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Bicillin C-R 900/300 is only indicated in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Not considered appropriate for the treatment of sexually transmitted diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. When high, sustained serum levels are required, use alternative penicillin preparations.</p></div>
<div class="block mst drugH1Div" id="F207735"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Penicillin may be confused with penicillAMINE</p>
<p style="text-indent:-2em;margin-left:4em;">Bicillin may be confused with Wycillin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Penicillin G benzathine should only be administered by deep intramuscular (IM) injection; IV administration of penicillin G benzathine has been associated with cardiopulmonary arrest and death.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Bicillin C-R (penicillin G benzathine and penicillin G procaine) may be confused with Bicillin L-A (penicillin G benzathine). Penicillin G benzathine is the only product currently approved for the treatment of syphilis. Administration of penicillin G benzathine and penicillin G procaine combination instead of Bicillin L-A may result in inadequate treatment response.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299840"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F207704"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Penicillins may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Penicillins may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F5715759"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">As a class, penicillin antibiotics are widely used in pregnant women. Based on available data, penicillin antibiotics are generally considered compatible for use during pregnancy (Ailes 2016; Bookstaver 2015; Crider 2009; Damkier 2019; Erić 2012; Heinonen 1977; Lamont 2014; Muanda 2017a; Muanda 2017b).</p>
<p style="text-indent:0em;margin-top:2em;">See individual monographs for additional information.</p></div>
<div class="block brc drugH1Div" id="F5715761"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Soluble penicillin G is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that caution be exercised when administering this combination to breastfeeding women. See individual monographs for additional information.</p></div>
<div class="block mop drugH1Div" id="F207708"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hypersensitivity reactions with first dose, injection-site reactions, periodic renal and hematologic function tests with prolonged therapy</p></div>
<div class="block pha drugH1Div" id="F207698"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F9951551"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: IM: Released slowly</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Highest levels in the kidney; lesser amounts in liver, skin, intestines</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~60%</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IM: Within 3 hours </p></div>
<div class="block phksp drugH1Div" id="F51159935"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Excretion of the drug is considerably delayed in neonates, children, and individuals with renal function impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58195732"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Bicillin cr</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27891788">
<a name="27891788"></a>Ailes EC, Gilboa SM, Gill SK, et al. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011. <i>Birth Defects Res A Clin Mol Teratol</i>. 2016;106(11):940-949. doi:10.1002/bdra.23570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information/abstract-text/27891788/pubmed" id="27891788" target="_blank">27891788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-765515">
<a name="765515"></a>Bass JW, Crast FW, Knowles CR, Onufer CN. Streptococcal pharyngitis in children: A comparison of four treatment schedules with intramuscular penicillin G benzathine. <i>JAMA</i>. 1976;235(11):1112-1116.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information/abstract-text/765515/pubmed" id="765515" target="_blank">765515</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Bicillin C-R (penicillin G benzathine and penicillin G procaine) [prescribing information]. New York, NY: Pfizer Inc; September 2021.</div>
</li>
<li>
<div class="reference">
                  Bicillin C-R (penicillin G benzathine and penicillin G procaine) [prescribing information]. New York, NY: Pfizer Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bicillin.2">
<a name="Bicillin.2"></a>Bicillin C-R 900/300 (penicillin G benzathine and penicillin G procaine) [prescribing information]. New York, NY: Pfizer Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bicillin.2">
<a name="Bicillin.2"></a>Bicillin C-R 900/300 (penicillin G benzathine and penicillin G procaine) [prescribing information]. New York, NY: Pfizer Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26598097">
<a name="26598097"></a>Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. <i>Pharmacotherapy</i>. 2015;35(11):1052-1062. doi:10.1002/phar.1649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information/abstract-text/26598097/pubmed" id="26598097" target="_blank">26598097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;53(7):e25-e76. doi:10.1093/cid/cir531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15758893">
<a name="15758893"></a>Centers for Disease Control and Prevention (CDC). Inadvertent use of <i>Bicillin C-R</i> to treat syphilis infection—Los Angeles, California, 1999-2004. <i>MMWR Morb Mortal Wkly Rep</i>. 2005;54(09):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information/abstract-text/15758893/pubmed" id="15758893" target="_blank">15758893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884587">
<a name="19884587"></a>Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. <i>Arch Pediatr Adolesc Med</i>. 2009;163(11):978-985. doi:10.1001/archpediatrics.2009.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information/abstract-text/19884587/pubmed" id="19884587" target="_blank">19884587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31260651">
<a name="31260651"></a>Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. <i>Am J Obstet Gynecol</i>. 2019;221(6):648.e1-648.e15. doi:10.1016/j.ajog.2019.06.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information/abstract-text/31260651/pubmed" id="31260651" target="_blank">31260651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22338555">
<a name="22338555"></a>Erić M, Leppée M, Sabo A, Culig J. Beta-lactam antibiotics during pregnancy: a cross-sectional comparative study Zagreb-Novi Sad. <i>Eur Rev Med Pharmacol Sci</i>. 2012;16(1):103-110.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information/abstract-text/22338555/pubmed" id="22338555" target="_blank">22338555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19246689">
<a name="19246689"></a>Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. <i>Circulation</i>. 2009;119(11):1541-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information/abstract-text/19246689/pubmed" id="19246689" target="_blank">19246689</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Heinonen OP, Slone D, Shapiro S. <i>Birth Defects and Drugs in Pregnancy</i>. Publishing Sciences Group Inc; 1977.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information/abstract-text/Heinonen.1/pubmed" id="Heinonen.1" target="_blank">Heinonen.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25189188">
<a name="25189188"></a>Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. <i>Expert Opin Drug Saf</i>. 2014;13(12):1569-1581. doi:10.1517/14740338.2014.939580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information/abstract-text/25189188/pubmed" id="25189188" target="_blank">25189188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23439909">
<a name="23439909"></a>Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. <i>Pediatrics</i>. 2013;131(3):e964-e999. doi:10.1542/peds.2012-3488<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information/abstract-text/23439909/pubmed" id="23439909" target="_blank">23439909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28722171">
<a name="28722171"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. <i>Br J Clin Pharmacol</i>. 2017a;83(11):2557-2571. doi:10.1111/bcp.13364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information/abstract-text/28722171/pubmed" id="28722171" target="_blank">28722171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28461374">
<a name="28461374"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. <i>CMAJ</i>. 2017b;189(17):E625-E633. doi:10.1503/cmaj.161020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information/abstract-text/28461374/pubmed" id="28461374" target="_blank">28461374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22965026">
<a name="22965026"></a>Shulman ST, Bisno AL, Clegg HW, et al; Infectious Diseased Society of America. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2012;55(10):e86-e102. doi:10.1093/cid/cis629<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information/abstract-text/22965026/pubmed" id="22965026" target="_blank">22965026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24973422">
<a name="24973422"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/penicillin-g-benzathine-and-penicillin-g-procaine-mixture-of-long-and-intermediate-acting-intramuscular-drug-information/abstract-text/24973422/pubmed" id="24973422" target="_blank">24973422</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9870 Version 183.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
